Advantus Capital Management Inc Boosts Position in Regeneron Pharmaceuticals, Inc. (REGN)
Advantus Capital Management Inc boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,885 shares of the biopharmaceutical company’s stock after buying an additional 148 shares during the quarter. Advantus Capital Management Inc owned approximately 7,358.84% of Regeneron Pharmaceuticals worth $3,526,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Fieldpoint Private Securities LLC bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $130,000. Sterling Investment Advisors Ltd. lifted its holdings in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares during the last quarter. FNY Partners Fund LP lifted its holdings in Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 200 shares during the last quarter. Alpha Windward LLC lifted its holdings in Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1 shares during the last quarter. Finally, IFP Advisors Inc lifted its holdings in Regeneron Pharmaceuticals by 33.2% during the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 96 shares during the last quarter. Institutional investors own 67.63% of the company’s stock.
In other news, Director Charles A. Baker sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the transaction, the director now owns 11,000 shares in the company, valued at $4,950,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The disclosure for this sale can be found here. Insiders sold 88,942 shares of company stock worth $42,064,076 in the last 90 days. Company insiders own 10.80% of the company’s stock.
Several research firms have commented on REGN. Citigroup Inc. reaffirmed a “buy” rating and set a $480.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $491.00 to $479.00 and set a “market perform” rating on the stock in a report on Thursday. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $490.00 to $463.00 and set an “equal weight” rating on the stock in a report on Thursday. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $425.00 price objective (down from $473.00) on shares of Regeneron Pharmaceuticals in a report on Thursday. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $472.00 price objective (up from $469.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Three equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $481.49.
COPYRIGHT VIOLATION WARNING: “Advantus Capital Management Inc Boosts Position in Regeneron Pharmaceuticals, Inc. (REGN)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/advantus-capital-management-inc-boosts-position-in-regeneron-pharmaceuticals-inc-regn/1696036.html.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $404.54 on Friday. The company has a quick ratio of 3.21, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $340.09 and a fifty-two week high of $543.55. The stock has a market cap of $43,525.81, a P/E ratio of 35.17, a PEG ratio of 1.40 and a beta of 1.56.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter last year, the business earned $3.13 earnings per share. The business’s revenue was up 23.0% on a year-over-year basis. research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.77 EPS for the current fiscal year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.